Eunjin Hong
Eunjin Hong
전공Clinical Pharmacokinetics, Clinical Pharmacology, Clinical Quantitative Pharmacology, Regulatory Science
연락처
031 881 7108
ejhong1@cha.ac.kr
학력
- 2012.03 - 2016.02 서울대학교 약학과 (약학사)
- 2020.01 - 2022.12 University of Southern California, Regulatory Science (규제과학 석사)
- 2017.08 - 2023.05 University of Southern California, Clinical Pharmacy (임상약학박사)
경력
- [경력]
- (현) 차의과학대학교 약학대학 조교수
- (현) 차의과학대학교 임상약학대학원 겸임교수
- University of Southern California, School of Pharmacy, 연구원
- 삼성바이오에피스 연구원
- Top Poster Recipient, American Society for Clinical Pharmacology and Therapeutics(ASCPT), 2023.03
- Top Abstract, North American Cystic Fibrosis Conference, 2021.10
- Best Teaching Assistant Award, University of Southern California, 2021.06
- Top Abstract, North American Cystic Fibrosis Conference, 2020.10
- Dean of the College of Pharmacy Award, Seoul National University, 2016.02
수상
논문
- 연구분야
- 본 연구실은 임상약동학(clinical pharmacokinetics) 및 계량약리학(pharmacometrics) 연구를 통하여, 약물의 약동학적 특성을 모델링 및 시뮬레이션하고, 이를 토대로 하여 의약품의 약효 및 부작용을 예측하고 다양한 환자군에 최적화된 맞춤 약물요법을 확립하기 위한 연구를 수행하고 있습니다. 또한, 생리학 기반 약물동태학(PBPK) 및 약동/약력학(PK/PD) 모델링을 포함한 다양한 모델링 기법을 활용하여, 임상시험 설계 및 약물 용량 최적화 등 신약개발과정에 필요한 의사결정의 근거를 제공하는 연구를 수행 중입니다.
- 1. Physiologically based pharmacokinetic modeling - Drug therapy optimization for special populations, Drug-drug interaction simulations
- 2. Model-informed drug development (MIDD) - clinical trial design, optimal dose selection
- Eunjin Hong, Alan Shi, Paul Beringer. (2023). “CFTR modulator drug interactions: a review of the evidence and clinical implications.” Expert Opinion on Drug Metabolism & Toxicology, 19(4), 203-216.
- Eunjin Hong, Eugeniu Carmanov, Alan Shi, Peter S Chung, Adupa P Rao, Kevin Forrester, Paul M Beringer. (2023). “Application of physiologically-based pharmacokinetic modeling to predict drug-drug interactions between ivacaftor and tacrolimus in lung transplant patients.” Pharmaceutics, 15(5), 1438.
- Tian Xia, Xin Wu, Eunjin Hong, Kyle Jung, Chih-Jen Lai, Mi-Jeong Kwak, Hogyu Seo, Stephanie Kim, Zhongyi Jiang, Inho Cha, Jae U Jung. (2023). “Glucosylceramide is essential for Heartland and Dabie bandavirus glycoprotein-induced membrane fusion.” PLoS Pathogen, 19(3), e1011232.
- Eunjin Hong, Regina Li, Alan Shi, Lisa M Almond, Joshua Wang, Amin Z Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S Chung, Adupa P Rao, Paul M Beringer. (2023). "Safety of elexacaftor/tezacaftor/ivacaftor dose reductions: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series." Pharmacotherapy, 43(4), 291-299.
- Eunjin Hong, Lisa Almond, Peter S Chung, Adupa P Rao, Paul M Beringer. (2022). "Physiologically-Based Pharmacokinetic (PBPK) modeling to guide management of drug interactions between elexacaftor-tezacaftor-ivacaftor and antibiotics for the treatment of non-tuberculosis mycobacteria (NTM)." Antimicrobial Agents and Chemotherapy, 66(11), e0110422.
- Eunjin Hong, Lisa Almond, Peter S Chung, Adupa P Rao, Paul M Beringer. (2022). "Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients with Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19." Clinical Pharmacology & Therapeutics, 111(6), 1324-1333.
- Weiqiang Chen, Suan-Sin Foo, Eunjin Hong, Christine Wu, Wai-Suet Lee, Shin-Ae Lee, Denis Evseenko, Maria Elisabeth Lopes Moreira, Adolfo García-Sastre, Genhong Cheng, Karin Nielsen-Saines, Patrícia Brasil, Elyzabeth Avvad-Portari, Jae U Jung. (2021). "Zika virus NS3 protease induces bone morphogenetic protein-dependent brain calcification in human fetuses." Nature Microbiology, 6(4), 455-466.
논문